Clinical trial · Interventional
Oxycodone in Combination With Parathoracic Nerve Block is Used for Postoperative Analgesia in Lung Cancer
Effect of Oxycodone Combined With Ultrasound Guided Thoracic Paravertebral Nerve Block on Postoperative Analgesia in Patients With Lung Cancer Undergoing Thoracoscopic Surgery
NCT05742256CI-TRIAL-00064179unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, the effect of oxycodone combined with ultrasound-guided paravertebral nerve block on the postoperative analgesic effect of thoracoscopic lung cancer was investigated, and the effect and reasonable dose of oxycodone were explored, which provided a reference for the clinical multimodal analgesia after thoracoscopic lung cancer surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oxycodone | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oxycodone 1.5mg/kg | Drug | — | UNRESOLVED |
| Oxycodone 1mg/kg | Drug | — | UNRESOLVED |
| Sufentanil | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Test group 1(OCA group)
- interventionNames
- Drug: Oxycodone 1mg/kg
- type
- EXPERIMENTAL
- label
- Test group 2(OCB group)
- interventionNames
- Drug: Oxycodone 1.5mg/kg
- type
- ACTIVE_COMPARATOR
- label
- Control group(SF group)
- interventionNames
- Drug: Sufentanil
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or female, age \> 60 years 2. Patients undergoing thoracoscopic lobectomy 3. ASA (American Academy of Anesthesiologists) Grades I-III 4. There were no obvious abnormalities in heart, liver, and kidney function 5. Sign the informed consent form for this clinical study Exclusion Criteria: 1. History of oxycodone or sufentanil allergy 2. Renal or hepatic dysfunction 3. History of drug or alcohol abuse 4. Psychiatric disorders: schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis 5. Those who have difficulty communicating due to coma, severe dementia, speech barrier, or those who cannot cooperate due to other diseases. 6. People with head trauma or other brain diseases -
References
Publications (1)
- DERIVEDWang Y, Wu G, Liu Z, Wei X, Feng H, Su J, Shi P. Effect of oxycodone combined with ultrasound-guided thoracic paravertebral nerve block on postoperative analgesia in patients with lung cancer undergoing thoracoscopic surgery: protocol for a randomised controlled study. BMJ Open. 2023 Oct 16;13(10):e074416. doi: 10.1136/bmjopen-2023-074416. PMID 37844986